TABLE II.

Retrospective studies of adjuvant radiation therapy

Reference	Pts (n)	Systemic treatment [n (%)]	Radiation		Local control [n (%)]
			Type [n (%)]	Dose (Gy)
Percarpio and Knowlton 197627	4	Not reported	Adjuvant	28–40	1 (25)
Nader et al., 198328	10	Not reported	Adjuvant [5 (50)]	Not reported	2 (20)
Markoe et al., 199129	5	Chemotherapy or mitotane [2 (40)]	Adjuvant	42–60	3 (60)
Pommier and Brennan, 199230	3	Not reported	Adjuvant	39–45	0/3
Crucitti et al., 199631	11	Chemoradiation [5 (45.5)]	Adjuvant	30–52	Not reported
Jacob et al., 200032	5	Chemoradiation [2 (40)]	Adjuvant	40–45	5 (100)
Fassnacht et al., 20063	14	5 (35.7)	Adjuvant	41.4–54	12 (85.7)
Hermsen et al., 201033	3	Not reported	Adjuvant	Not reported	3 (100)
Sabloch et al., 201134	10	No	Adjuvant [10 (38.5)]	45–57	8 (80)
	16		Definitive [16 (61.5)]	22.5–73.51	5 (31.3)
Habra et al., 20134	16	4 (25)	Adjuvant	36–59.4	9 (56.3)
Ho et al., 201335	14	Chemoradiation 7 (50)	Adjuvant [2 (14.3)]	17.5–60	Of the 2 adjuvant patients, both experienced out-of-field recurrence
			Palliative [12 (85.7)]	50.4–60
Else et al., 20145	59	Mitotane [42 (71.2) radiation and mitotane]	Adjuvant	Not reported	Not reported. Significant interaction observed between adjuvant mitotane and adjuvant radiation for recurrence-free survival when integrated in one model (hazard ratio: 0.4; p=0.03)
Sabolch et al., 201526	20a	Mitotane concurrent with radiation	Adjuvant	45–60	Adjuvant radiation: 19 (95) Control groupa: 8 (40) (p=0.0005)

^aThe 20 patients treated with adjuvant radiation were matched to 20 surgical control subjects not treated with radiation. Matching was based on stage, grade, margins, and adjuvant mitotane.